Stay updated on CM-24 Combo Study With Pembrolizumab Clinical Trial
Sign up to get notified when there's something new on the CM-24 Combo Study With Pembrolizumab Clinical Trial page.

Latest updates to the CM-24 Combo Study With Pembrolizumab Clinical Trial page
- Check5 days agoChange DetectedPage revision updated from v3.5.0 to v3.5.2.SummaryDifference0.0%

- Check12 days agoNo Change Detected
- Check20 days agoNo Change Detected
- Check34 days agoChange DetectedRevision: v3.5.0 is now displayed, replacing the previous Revision: v3.4.3.SummaryDifference0.0%

- Check49 days agoChange DetectedRevision label updated from v3.4.2 to v3.4.3. This update does not change the study details or site content.SummaryDifference0.0%

- Check70 days agoChange DetectedGastric cancer was added to the list of studied conditions and a Genetics/Rare Diseases Information Center resource was included. The page revision was updated from v3.4.1 to v3.4.2.SummaryDifference0.2%

- Check77 days agoChange DetectedRevision: v3.4.1 was added and v3.4.0 was removed. This change does not affect study data, eligibility, or functionality; to avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check91 days agoChange DetectedThe page now includes a glossary toggle (Show glossary) and displays a new 'Last Update Submitted that Met QC Criteria' indicator, along with a site revision note 'Revision: v3.4.0'. The previous elements 'Last Update Submitted that met QC Criteria', 'No FEAR Act data', and 'Revision: v3.3.4' were removed.SummaryDifference0.2%

Stay in the know with updates to CM-24 Combo Study With Pembrolizumab Clinical Trial
Enter your email address, and we'll notify you when there's something new on the CM-24 Combo Study With Pembrolizumab Clinical Trial page.